PODCAST

Risk and compliance response to COVID-19 in the life sciences industry

Duleep Rodrigo talks with compliance executives on how the life science industry has been widely impacted by the scale of COVID-19.

Duleep Rodrigo

Duleep Rodrigo

Consulting Industry Leader, Consumer & Retail, KPMG US

+1 213-817-3150

Like most sectors, the life science industry has been widely impacted by the scale and nature of the global pandemic. The abrupt cessation of face-to-face interactions, along with the massive move to remote work has required the audit function to re-evaluate risk assessments and priorities. All prior monitoring, plans, and policies are being challenged to ensure that they represent the best use of audit resources and client time in a COVID-19 environment.

Amgen and Teva Pharmaceutical compliance executives, in conversation with Duleep Rodrigo from KPMG, discuss:

  • why addressing culture must come before any change factors may be considered
  • how telemedicine, virtual pharma sales reps, and a proliferation of donations have created unique compliance risks
  • examples of predictive analytics that spot anomalies in behavior and detect fraud
  • specific ways to make remote auditing more effective
  • how the compliance model can support the business model to help anticipate future pressure points
  • novel ways to create audit team visibility.

KPMG moderator

Duleep Rodrigo

Duleep Rodrigo

Consulting Industry Leader, Consumer & Retail, KPMG US

Guest presenters

Annette Such

Annette Such

Vice President and Chief Audit Executive, Amgen

Lori Queisser

Lori Queisser

Senior Vice President and Global Compliance Officer, Teva Pharmaceutical Industries Ltd.

Related content